| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatomyositis | 9 | 2019 | 18 | 2.680 |
Why?
|
| Immunosuppressive Agents | 11 | 2018 | 248 | 2.350 |
Why?
|
| Keratosis | 10 | 2008 | 22 | 2.020 |
Why?
|
| Gingivitis | 3 | 2018 | 5 | 1.670 |
Why?
|
| Dermatologic Agents | 11 | 2020 | 233 | 1.640 |
Why?
|
| Skin Diseases | 4 | 2021 | 135 | 1.540 |
Why?
|
| Methotrexate | 10 | 2020 | 70 | 1.400 |
Why?
|
| Keratosis, Actinic | 5 | 2014 | 20 | 1.400 |
Why?
|
| Aminoquinolines | 7 | 2010 | 18 | 1.360 |
Why?
|
| Photosensitivity Disorders | 7 | 2008 | 12 | 1.290 |
Why?
|
| Pyoderma Gangrenosum | 4 | 2019 | 12 | 1.280 |
Why?
|
| Fluorouracil | 8 | 2014 | 79 | 1.270 |
Why?
|
| Pemphigus | 3 | 2018 | 8 | 1.180 |
Why?
|
| Humans | 81 | 2021 | 32284 | 1.170 |
Why?
|
| Lichen Planus, Oral | 3 | 2018 | 11 | 1.150 |
Why?
|
| Skin Diseases, Vascular | 3 | 2020 | 11 | 1.120 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 2 | 2018 | 3 | 1.100 |
Why?
|
| Tacrolimus | 3 | 2018 | 66 | 1.090 |
Why?
|
| Skin Neoplasms | 5 | 2013 | 220 | 1.040 |
Why?
|
| Skin | 8 | 2019 | 213 | 0.990 |
Why?
|
| Wound Healing | 3 | 2019 | 184 | 0.960 |
Why?
|
| Lupus Erythematosus, Cutaneous | 3 | 2019 | 13 | 0.790 |
Why?
|
| Male | 42 | 2020 | 19447 | 0.780 |
Why?
|
| Skin Ulcer | 2 | 2020 | 12 | 0.720 |
Why?
|
| Adult | 33 | 2020 | 9262 | 0.720 |
Why?
|
| Female | 43 | 2020 | 19953 | 0.700 |
Why?
|
| Hydroxychloroquine | 2 | 2019 | 11 | 0.690 |
Why?
|
| Morgellons Disease | 2 | 2018 | 3 | 0.690 |
Why?
|
| Antipsychotic Agents | 2 | 2018 | 30 | 0.670 |
Why?
|
| Prednisone | 6 | 2013 | 69 | 0.670 |
Why?
|
| Treatment Outcome | 17 | 2020 | 3409 | 0.660 |
Why?
|
| Lichen Sclerosus et Atrophicus | 3 | 2017 | 10 | 0.650 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2014 | 156 | 0.640 |
Why?
|
| Middle Aged | 30 | 2020 | 11847 | 0.640 |
Why?
|
| Telangiectasis | 1 | 2020 | 5 | 0.640 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2014 | 48 | 0.630 |
Why?
|
| Acanthosis Nigricans | 1 | 2020 | 3 | 0.620 |
Why?
|
| Cryosurgery | 5 | 2014 | 25 | 0.620 |
Why?
|
| Scleroderma, Localized | 2 | 2017 | 6 | 0.620 |
Why?
|
| Stomatitis, Aphthous | 3 | 2005 | 4 | 0.600 |
Why?
|
| Trifluoperazine | 2 | 2018 | 4 | 0.580 |
Why?
|
| Glossitis, Benign Migratory | 1 | 2018 | 2 | 0.580 |
Why?
|
| Diagnosis, Differential | 11 | 2018 | 501 | 0.560 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2019 | 38 | 0.560 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 186 | 0.560 |
Why?
|
| Insulin | 1 | 2020 | 359 | 0.540 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 167 | 0.530 |
Why?
|
| Mycophenolic Acid | 5 | 2015 | 42 | 0.520 |
Why?
|
| Administration, Topical | 9 | 2018 | 142 | 0.510 |
Why?
|
| Prognosis | 7 | 2018 | 1529 | 0.500 |
Why?
|
| Biopsy, Needle | 7 | 2018 | 93 | 0.500 |
Why?
|
| Vasculitis | 2 | 2018 | 26 | 0.490 |
Why?
|
| Aged, 80 and over | 14 | 2020 | 3899 | 0.490 |
Why?
|
| Facial Dermatoses | 2 | 2007 | 18 | 0.470 |
Why?
|
| Aged | 24 | 2020 | 10258 | 0.460 |
Why?
|
| Drug Administration Schedule | 7 | 2018 | 276 | 0.460 |
Why?
|
| Dermatitis, Atopic | 2 | 2017 | 103 | 0.450 |
Why?
|
| Neutrophils | 2 | 2014 | 120 | 0.450 |
Why?
|
| Adolescent | 14 | 2020 | 3518 | 0.450 |
Why?
|
| Clobetasol | 1 | 2015 | 26 | 0.440 |
Why?
|
| Retrospective Studies | 11 | 2020 | 3612 | 0.440 |
Why?
|
| Behcet Syndrome | 3 | 2005 | 5 | 0.440 |
Why?
|
| Alopecia | 2 | 2021 | 29 | 0.440 |
Why?
|
| Colitis, Ulcerative | 1 | 2014 | 24 | 0.420 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2014 | 28 | 0.420 |
Why?
|
| Arthritis | 1 | 2014 | 30 | 0.420 |
Why?
|
| Dermatitis | 4 | 2015 | 20 | 0.410 |
Why?
|
| Precancerous Conditions | 2 | 2013 | 23 | 0.410 |
Why?
|
| Severity of Illness Index | 7 | 2018 | 854 | 0.400 |
Why?
|
| Acne Vulgaris | 3 | 2010 | 101 | 0.390 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2012 | 5 | 0.370 |
Why?
|
| Pemphigoid, Bullous | 1 | 2012 | 9 | 0.360 |
Why?
|
| Carcinoma | 1 | 2012 | 92 | 0.350 |
Why?
|
| Algorithms | 2 | 2012 | 536 | 0.340 |
Why?
|
| Administration, Cutaneous | 8 | 2014 | 116 | 0.330 |
Why?
|
| Immunohistochemistry | 6 | 2018 | 544 | 0.330 |
Why?
|
| Child | 10 | 2017 | 2432 | 0.330 |
Why?
|
| Hutchinson's Melanotic Freckle | 1 | 2010 | 2 | 0.320 |
Why?
|
| Antifungal Agents | 2 | 2007 | 44 | 0.300 |
Why?
|
| Ointments | 6 | 2010 | 23 | 0.300 |
Why?
|
| Skin Aging | 1 | 2009 | 9 | 0.300 |
Why?
|
| Combined Modality Therapy | 7 | 2014 | 550 | 0.300 |
Why?
|
| Child, Preschool | 7 | 2017 | 1234 | 0.300 |
Why?
|
| Ants | 1 | 2008 | 1 | 0.290 |
Why?
|
| Bedding and Linens | 1 | 2008 | 4 | 0.290 |
Why?
|
| Glomus Tumor | 1 | 2008 | 4 | 0.290 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2015 | 115 | 0.280 |
Why?
|
| Lichen Planus | 2 | 2020 | 10 | 0.280 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2008 | 19 | 0.280 |
Why?
|
| Tretinoin | 1 | 2008 | 33 | 0.280 |
Why?
|
| Double-Blind Method | 7 | 2010 | 567 | 0.280 |
Why?
|
| Keratolytic Agents | 1 | 2008 | 29 | 0.280 |
Why?
|
| Curettage | 1 | 2007 | 7 | 0.260 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2007 | 27 | 0.260 |
Why?
|
| Scalp Dermatoses | 1 | 2007 | 18 | 0.250 |
Why?
|
| Anti-Bacterial Agents | 4 | 2018 | 325 | 0.250 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2018 | 99 | 0.250 |
Why?
|
| Disease Progression | 3 | 2018 | 591 | 0.250 |
Why?
|
| Tinea Pedis | 1 | 2006 | 4 | 0.250 |
Why?
|
| Physical Examination | 2 | 2018 | 83 | 0.250 |
Why?
|
| Medication Adherence | 2 | 2018 | 160 | 0.250 |
Why?
|
| Thiophenes | 1 | 2006 | 24 | 0.240 |
Why?
|
| Lupus Erythematosus, Systemic | 4 | 2014 | 149 | 0.240 |
Why?
|
| Quality of Life | 2 | 2017 | 970 | 0.240 |
Why?
|
| Imidazoles | 1 | 2006 | 97 | 0.240 |
Why?
|
| Cryotherapy | 2 | 2004 | 12 | 0.240 |
Why?
|
| Polychondritis, Relapsing | 1 | 2006 | 2 | 0.240 |
Why?
|
| Granuloma, Pyogenic | 1 | 2006 | 5 | 0.240 |
Why?
|
| Adjuvants, Immunologic | 2 | 2004 | 61 | 0.230 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 821 | 0.220 |
Why?
|
| Sunlight | 3 | 2013 | 17 | 0.220 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 43 | 0.220 |
Why?
|
| Cosmetic Techniques | 1 | 2004 | 11 | 0.220 |
Why?
|
| Antineoplastic Agents | 2 | 2007 | 595 | 0.210 |
Why?
|
| Recurrence | 4 | 2007 | 286 | 0.210 |
Why?
|
| Physical Therapy Modalities | 1 | 2004 | 81 | 0.210 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 129 | 0.210 |
Why?
|
| Follow-Up Studies | 6 | 2018 | 2238 | 0.210 |
Why?
|
| United States | 5 | 2018 | 4077 | 0.200 |
Why?
|
| Drug Therapy, Combination | 5 | 2014 | 293 | 0.200 |
Why?
|
| Risk Assessment | 3 | 2018 | 1423 | 0.190 |
Why?
|
| Interferon Inducers | 1 | 2002 | 2 | 0.190 |
Why?
|
| Warts | 1 | 2002 | 3 | 0.190 |
Why?
|
| Salicylic Acid | 1 | 2002 | 6 | 0.190 |
Why?
|
| Microspheres | 3 | 2008 | 45 | 0.180 |
Why?
|
| Granuloma | 1 | 2002 | 14 | 0.180 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2002 | 37 | 0.180 |
Why?
|
| Azathioprine | 2 | 2015 | 27 | 0.180 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2002 | 6 | 0.180 |
Why?
|
| Clinical Trials as Topic | 3 | 2017 | 312 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2018 | 716 | 0.170 |
Why?
|
| Thalidomide | 4 | 2007 | 32 | 0.170 |
Why?
|
| Erythema Multiforme | 1 | 2021 | 1 | 0.170 |
Why?
|
| Urticaria | 1 | 2021 | 1 | 0.170 |
Why?
|
| Pityriasis Rosea | 1 | 2021 | 1 | 0.170 |
Why?
|
| Purpura | 1 | 2021 | 4 | 0.170 |
Why?
|
| Chilblains | 1 | 2021 | 4 | 0.170 |
Why?
|
| Livedo Reticularis | 1 | 2021 | 2 | 0.170 |
Why?
|
| Cyanosis | 1 | 2021 | 3 | 0.170 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2021 | 5 | 0.170 |
Why?
|
| Drug Eruptions | 1 | 2021 | 9 | 0.170 |
Why?
|
| Gels | 4 | 2010 | 31 | 0.160 |
Why?
|
| Benzoyl Peroxide | 2 | 2010 | 20 | 0.160 |
Why?
|
| Naphthalenes | 2 | 2010 | 53 | 0.160 |
Why?
|
| Vulvar Diseases | 1 | 2020 | 5 | 0.160 |
Why?
|
| Creatine Kinase | 1 | 2019 | 7 | 0.150 |
Why?
|
| Laser Therapy | 1 | 2020 | 51 | 0.150 |
Why?
|
| Muscular Diseases | 1 | 2019 | 23 | 0.150 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 245 | 0.150 |
Why?
|
| Pruritus | 2 | 2012 | 46 | 0.150 |
Why?
|
| Wound Infection | 1 | 2018 | 11 | 0.140 |
Why?
|
| Leg | 1 | 2019 | 67 | 0.140 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2018 | 12 | 0.140 |
Why?
|
| Swine | 1 | 2019 | 228 | 0.140 |
Why?
|
| Neoplasm Staging | 2 | 2010 | 458 | 0.130 |
Why?
|
| Remission Induction | 3 | 2013 | 92 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 150 | 0.130 |
Why?
|
| Patient Compliance | 2 | 2013 | 206 | 0.130 |
Why?
|
| Drug Resistance | 1 | 2017 | 42 | 0.130 |
Why?
|
| Steroids | 1 | 2017 | 35 | 0.130 |
Why?
|
| Nausea | 1 | 2017 | 50 | 0.130 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 179 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2020 | 458 | 0.130 |
Why?
|
| Mother-Child Relations | 1 | 2017 | 13 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 161 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2018 | 367 | 0.120 |
Why?
|
| Darier Disease | 1 | 2016 | 2 | 0.120 |
Why?
|
| Young Adult | 3 | 2018 | 2651 | 0.120 |
Why?
|
| Glucocorticoids | 2 | 2015 | 146 | 0.120 |
Why?
|
| Urinary Bladder | 1 | 2019 | 320 | 0.120 |
Why?
|
| Activities of Daily Living | 1 | 2017 | 246 | 0.110 |
Why?
|
| Stress, Psychological | 1 | 2017 | 229 | 0.110 |
Why?
|
| Syndrome | 1 | 2014 | 66 | 0.110 |
Why?
|
| Panniculitis, Lupus Erythematosus | 1 | 2014 | 6 | 0.110 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2014 | 7 | 0.100 |
Why?
|
| Retinal Vasculitis | 1 | 2014 | 1 | 0.100 |
Why?
|
| Sweet Syndrome | 1 | 2014 | 6 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2015 | 411 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2018 | 1840 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2012 | 2317 | 0.100 |
Why?
|
| Nurse Practitioners | 1 | 2013 | 12 | 0.090 |
Why?
|
| Animals | 2 | 2019 | 8197 | 0.090 |
Why?
|
| Singapore | 1 | 2012 | 7 | 0.090 |
Why?
|
| International Agencies | 1 | 2012 | 10 | 0.090 |
Why?
|
| Calcium Compounds | 1 | 2012 | 9 | 0.090 |
Why?
|
| Diphosphonates | 1 | 2012 | 9 | 0.090 |
Why?
|
| Oxides | 1 | 2012 | 17 | 0.090 |
Why?
|
| Bone Density Conservation Agents | 1 | 2012 | 23 | 0.090 |
Why?
|
| Erythema | 1 | 2012 | 25 | 0.090 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2012 | 101 | 0.090 |
Why?
|
| Physician Assistants | 1 | 2013 | 39 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2013 | 123 | 0.090 |
Why?
|
| Immunosuppression | 1 | 2012 | 118 | 0.090 |
Why?
|
| Pityriasis Lichenoides | 1 | 2011 | 4 | 0.090 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2011 | 9 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2018 | 555 | 0.090 |
Why?
|
| Herpes Simplex | 1 | 2011 | 14 | 0.090 |
Why?
|
| Muscle Strength | 1 | 2012 | 136 | 0.090 |
Why?
|
| Blood Vessels | 1 | 2012 | 58 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 1437 | 0.090 |
Why?
|
| Risk Factors | 3 | 2014 | 3936 | 0.080 |
Why?
|
| Dietary Supplements | 1 | 2012 | 189 | 0.080 |
Why?
|
| Vitamin D | 1 | 2012 | 186 | 0.080 |
Why?
|
| Cross-Over Studies | 1 | 2010 | 96 | 0.080 |
Why?
|
| Dermoscopy | 1 | 2010 | 12 | 0.080 |
Why?
|
| Doxycycline | 1 | 2010 | 26 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2010 | 545 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 65 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 388 | 0.070 |
Why?
|
| Emulsions | 2 | 2007 | 8 | 0.070 |
Why?
|
| Mastocytosis, Cutaneous | 1 | 2008 | 3 | 0.070 |
Why?
|
| European Continental Ancestry Group | 1 | 2012 | 1076 | 0.070 |
Why?
|
| Pedigree | 1 | 2008 | 136 | 0.070 |
Why?
|
| Alkylating Agents | 1 | 2008 | 5 | 0.070 |
Why?
|
| Drug Carriers | 1 | 2008 | 22 | 0.070 |
Why?
|
| Plasma Exchange | 1 | 2008 | 13 | 0.070 |
Why?
|
| Cyclosporine | 1 | 2008 | 48 | 0.070 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2008 | 24 | 0.070 |
Why?
|
| Mouth Mucosa | 1 | 2008 | 30 | 0.070 |
Why?
|
| Acute Disease | 1 | 2008 | 253 | 0.070 |
Why?
|
| Administration, Oral | 4 | 2010 | 200 | 0.070 |
Why?
|
| Laser-Doppler Flowmetry | 1 | 2007 | 34 | 0.070 |
Why?
|
| Fatigue | 1 | 2007 | 80 | 0.060 |
Why?
|
| Dermatomycoses | 1 | 2007 | 7 | 0.060 |
Why?
|
| Headache | 1 | 2007 | 72 | 0.060 |
Why?
|
| Skin Diseases, Infectious | 1 | 2006 | 2 | 0.060 |
Why?
|
| Cephalexin | 1 | 2006 | 2 | 0.060 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2006 | 4 | 0.060 |
Why?
|
| Streptococcus pyogenes | 1 | 2006 | 16 | 0.060 |
Why?
|
| Streptococcal Infections | 1 | 2006 | 23 | 0.060 |
Why?
|
| Lipids | 1 | 2007 | 254 | 0.060 |
Why?
|
| Exercise Therapy | 1 | 2008 | 249 | 0.060 |
Why?
|
| Fingers | 1 | 2006 | 75 | 0.060 |
Why?
|
| Therapeutic Equivalency | 1 | 2004 | 2 | 0.050 |
Why?
|
| Hepatitis, Autoimmune | 1 | 2005 | 7 | 0.050 |
Why?
|
| Lichenoid Eruptions | 1 | 2004 | 1 | 0.050 |
Why?
|
| Fluocinonide | 2 | 2018 | 11 | 0.050 |
Why?
|
| Scleroderma, Systemic | 1 | 2004 | 8 | 0.050 |
Why?
|
| Sunscreening Agents | 1 | 2004 | 12 | 0.050 |
Why?
|
| Diclofenac | 1 | 2004 | 3 | 0.050 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2004 | 13 | 0.050 |
Why?
|
| Aminolevulinic Acid | 1 | 2004 | 8 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2004 | 48 | 0.050 |
Why?
|
| Photosensitizing Agents | 1 | 2004 | 16 | 0.050 |
Why?
|
| Photochemotherapy | 1 | 2004 | 14 | 0.050 |
Why?
|
| Patient Selection | 1 | 2004 | 272 | 0.050 |
Why?
|
| Ulcer | 1 | 2003 | 2 | 0.050 |
Why?
|
| Genital Diseases, Female | 1 | 2003 | 4 | 0.050 |
Why?
|
| Oral Ulcer | 1 | 2003 | 6 | 0.050 |
Why?
|
| Least-Squares Analysis | 1 | 2002 | 32 | 0.050 |
Why?
|
| Toes | 1 | 2002 | 13 | 0.050 |
Why?
|
| Heel | 1 | 2002 | 7 | 0.050 |
Why?
|
| Age of Onset | 1 | 2003 | 91 | 0.050 |
Why?
|
| Life Style | 1 | 2004 | 394 | 0.050 |
Why?
|
| Hand | 1 | 2002 | 81 | 0.040 |
Why?
|
| Infant | 3 | 2011 | 1010 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2002 | 174 | 0.040 |
Why?
|
| Age Distribution | 1 | 2002 | 194 | 0.040 |
Why?
|
| Psoriasis | 1 | 2005 | 355 | 0.040 |
Why?
|
| Drug Combinations | 2 | 2010 | 102 | 0.040 |
Why?
|
| Risperidone | 1 | 2018 | 4 | 0.040 |
Why?
|
| Incidence | 1 | 2002 | 1243 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2018 | 68 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 86 | 0.030 |
Why?
|
| Wrist | 1 | 2017 | 44 | 0.030 |
Why?
|
| Nails | 1 | 2016 | 6 | 0.030 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2016 | 10 | 0.030 |
Why?
|
| Disease Management | 1 | 2016 | 129 | 0.030 |
Why?
|
| Postoperative Care | 1 | 2014 | 79 | 0.030 |
Why?
|
| Ophthalmoscopy | 1 | 2014 | 8 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2014 | 42 | 0.030 |
Why?
|
| Outpatients | 1 | 2014 | 57 | 0.030 |
Why?
|
| Vision Disorders | 1 | 2014 | 23 | 0.030 |
Why?
|
| Calcinosis | 1 | 2014 | 142 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2014 | 184 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2014 | 111 | 0.020 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2012 | 8 | 0.020 |
Why?
|
| Antibodies, Antinuclear | 1 | 2012 | 17 | 0.020 |
Why?
|
| Lupus Nephritis | 1 | 2012 | 29 | 0.020 |
Why?
|
| Vancomycin | 1 | 2011 | 17 | 0.020 |
Why?
|
| Clindamycin | 1 | 2011 | 21 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 249 | 0.020 |
Why?
|
| DNA | 1 | 2012 | 223 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 556 | 0.020 |
Why?
|
| Mechlorethamine | 1 | 2010 | 1 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 1484 | 0.020 |
Why?
|
| Silver Sulfadiazine | 1 | 2008 | 4 | 0.020 |
Why?
|
| Mast Cells | 1 | 2008 | 13 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2008 | 24 | 0.020 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2008 | 20 | 0.020 |
Why?
|
| Lip | 1 | 2008 | 7 | 0.020 |
Why?
|
| Hypopigmentation | 1 | 2008 | 7 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 2203 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2007 | 85 | 0.020 |
Why?
|
| Intertrigo | 1 | 2007 | 1 | 0.020 |
Why?
|
| Mitosporic Fungi | 1 | 2007 | 2 | 0.020 |
Why?
|
| Dermatitis, Seborrheic | 1 | 2007 | 4 | 0.020 |
Why?
|
| Gram-Positive Bacteria | 1 | 2007 | 3 | 0.020 |
Why?
|
| Tinea | 1 | 2007 | 5 | 0.020 |
Why?
|
| Retinoids | 1 | 2007 | 42 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2007 | 78 | 0.020 |
Why?
|
| Diterpenes | 1 | 2006 | 22 | 0.020 |
Why?
|
| Methicillin Resistance | 1 | 2006 | 24 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 2006 | 55 | 0.020 |
Why?
|
| Macrophages | 1 | 2007 | 207 | 0.010 |
Why?
|
| Cytokines | 1 | 2007 | 237 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 880 | 0.010 |
Why?
|
| Dermatology | 1 | 2007 | 157 | 0.010 |
Why?
|
| Myxedema | 1 | 2004 | 3 | 0.010 |
Why?
|
| Paraproteinemias | 1 | 2004 | 3 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2006 | 666 | 0.010 |
Why?
|
| Inflammation | 1 | 2007 | 507 | 0.010 |
Why?
|
| Prevalence | 1 | 2004 | 955 | 0.010 |
Why?
|